Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Comment by stormrideron Apr 06, 2020 11:57pm
102 Views
Post# 30885458

RE:website link

RE:website linkReading through the website this is our team :

Dr. Robert Kozak, Dr. Samira Mubareka and Dr. Arinjay Banerjee, who were the world’s first team to isolate the virus that causes COVID-19.Sunnybrook has been at the global forefront of the COVID-19 pandemic since the first Canadian case was identified. Our clinical response was immediate, but crucially, so was our research response.

Drs. Samira Mubareka and Robert Kozak have led Sunnybrook’s research response efforts since
the earliest days of the pandemic. Their work has been globally significant, leading to early implementation of a hospital-based COVID-19 test. That test now serves at least six major hospitals and their associated assessment centres, including Sunnybrook. Our team has also established the foundation for a viral genomics research program that has already made important contributions to COVID-19 analysis.

Most crucially, on March 10, 2020, Sunnybrook scientists isolated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the ongoing outbreak of COVID-19.


<< Previous
Bullboard Posts
Next >>